Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong

Abstract Background There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). We compared risk of stroke with its subtypes and incident atrial fibrillation (AF) between them. M...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Cardiovascular Diabetology
المؤلفون الرئيسيون:	David Tak Wai Lui, Eric Ho Man Tang, Tingting Wu, Ivan Chi Ho Au, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2023-02-01
الموضوعات:	Sodium-glucose cotransporter 2 inhibitors Glucagon-like peptide-1 receptor agonists Stroke Ischemic stroke Atrial fibrillation
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12933-023-01772-0

مواد مشابهة

The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
حسب: M. B. Antsiferov, وآخرون
منشور في: (2023-05-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
حسب: Jian‐Yu Jhu, وآخرون
منشور في: (2025-02-01)

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
حسب: Masato Shikata, وآخرون
منشور في: (2020-12-01)

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
حسب: Bruno Vergès, وآخرون
منشور في: (2022-11-01)

Glucagon-Like Peptide-1 Receptor Agonists in the Prevention of Ischemic Stroke: Therapeutic Potential and Mechanisms
حسب: Zhenzong Lin, وآخرون
منشور في: (2025-09-01)

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
حسب: Maria Antonietta Riemma, وآخرون
منشور في: (2024-06-01)

First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
حسب: Rui Deng, وآخرون
منشور في: (2024-01-01)

Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study
حسب: Oscar Hou‐In Chou, وآخرون
منشور في: (2025-06-01)

An integrated approach for obesity management: the effectiveness of glucagon-like peptide 1 agonist and life-style interventions for obesity management
حسب: A.V. Dinets, وآخرون
منشور في: (2022-05-01)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
حسب: Pierre Gourdy, وآخرون
منشور في: (2023-04-01)

Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes
حسب: Jun-Jun Yeh, وآخرون
منشور في: (2024-02-01)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
حسب: Yi-Hsin Chan, وآخرون
منشور في: (2022-06-01)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes
حسب: Ignatios Ikonomidis, وآخرون
منشور في: (2025-03-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
حسب: Agnieszka Jakubowska, وآخرون
منشور في: (2024-02-01)

Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes
حسب: Hun Jee Choe, وآخرون
منشور في: (2025-02-01)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
حسب: Jimmy Gonzalez, وآخرون
منشور في: (2023-03-01)

Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
حسب: Inês Henriques Vieira, وآخرون
منشور في: (2024-05-01)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
حسب: Lixin Du, وآخرون
منشور في: (2022-10-01)

State‐Level Variation in Glucagon‐Like Peptide‐1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023
حسب: Tamkeen Khan, وآخرون
منشور في: (2025-08-01)

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
حسب: Vaia Lambadiari, وآخرون
منشور في: (2021-08-01)

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
حسب: Yen-Chieh Lee, وآخرون
منشور في: (2022-09-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
حسب: Minara S. Shamkhalova, وآخرون
منشور في: (2020-04-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
حسب: Eric J. Brandt, وآخرون
منشور في: (2025-06-01)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
حسب: Tzu-Yi Lin, وآخرون
منشور في: (2023-05-01)

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
حسب: Toshiko Kobori, وآخرون
منشور في: (2023-06-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
حسب: Hirotaka Watada
منشور في: (2025-02-01)

Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care
حسب: Shahini Winson Gnanathayalan, وآخرون
منشور في: (2024-01-01)

The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment
حسب: Haohui Sun, وآخرون
منشور في: (2025-03-01)

Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
حسب: Pranjal Sharma, وآخرون
منشور في: (2024-08-01)

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
حسب: Xi Tan, وآخرون
منشور في: (2023-11-01)

Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study
حسب: Joana Freitas, وآخرون
منشور في: (2024-04-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
حسب: Ze-jin Liao, وآخرون
منشور في: (2024-12-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
حسب: Khang Duy Ricky Le, وآخرون
منشور في: (2024-01-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
حسب: Ekaterina V. Tikhonenko, وآخرون
منشور في: (2018-12-01)

Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis
حسب: Mohamed E. A. Mostafa, وآخرون
منشور في: (2025-03-01)

The role of sodium glucose cotransporter or glucagon-like peptide-1 receptor agonists in treating heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus
حسب: Laura Lungeanu-Juravle, وآخرون
منشور في: (2024-03-01)

Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
حسب: Chunyan Liu, وآخرون
منشور في: (2024-01-01)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
حسب: Marta Baviera, وآخرون
منشور في: (2022-08-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
حسب: Richard J. MacIsaac, وآخرون
منشور في: (2024-10-01)

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
حسب: Hae Young Lee, وآخرون
منشور في: (2024-09-01)